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The breast cancer 1 (brca1) gene is associated with breast and ovarian cancers, and heterozygous (þ/)
brca1 knockout progeny develop normally, suggesting a negligible developmental impact. However, our
results show BRCA1 plays a broader biological role in protecting the embryo from oxidative stress. Sox2-
promoted Cre-expressing hemizygous males were mated with ﬂoxed brca1 females, and gestational day
8 þ/ brca1 conditional knockout embryos with a 28% reduction in protein expression were exposed in
culture to the reactive oxygen species (ROS)-initiating drug ethanol (EtOH). Untreated þ/ brca1-de-
ﬁcient embryos developed normally, but when exposed to EtOH exhibited increased levels of oxidatively
damaged DNA, measured as 8-oxo-2'-deoxyguanosine, γH2AX, which is a marker of DNA double strand
breaks that can result from 8-oxo-2'-deoxyguanosine, formation, and embryopathies at EtOH con-
centrations that did not affect their brca1-normal littermates. These results reveal that even modest
BRCA1 deﬁciencies render the embryo more susceptible to drug-enhanced ROS formation, and corro-
borate a role for DNA oxidation in the mechanism of EtOH teratogenesis.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Brca1 is a DNA repair gene commonly associated with certain
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Avenue South, Birmingham,have shown that mice lacking both copies of the brca1 gene have
poor genomic integrity and are not viable [2]. The morphological
basis has been characterized by rapid disorganized proliferation of
neuroepithelium and increased cell death [3]. However, progeny
missing only one copy of the brca1 gene appear to develop nor-
mally [3], suggesting that minor BRCA1 deﬁciencies have a negli-
gible developmental impact.
A number of population-based studies have investigated the
developmental consequences of brca1 mutations on sex differ-
ences, miscarriage rates and prevalence of mutation carriers as
well as double mutants. While it has been suggested in small
population studies that there are differences in birth rates and sex
ratios [4,5], this has not been conﬁrmed in larger population stu-
dies [6,7]. Clinically, there have been no conﬁrmed cases of a viable
individual with two mutated copies of the brca1 gene [8], although
screening of lymphocyte DNA from patients in Scotland with
breast or ovarian cancer revealed a woman who lacked the wild-
type allele for brca1, and was the offspring of two carriers of the
brca1 mutation [9]. However, the ﬁnding that this individual car-
ried two copies of the mutated gene was likely the result of a
technical error in the screening method [10]. Taken together, po-
pulation studies on brca1 mutations and embryonic development
suggest that double mutants are not viable, while heterozygous
carriers of the mutation develop normally but are morender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The BRCA1 protein contains a ring domain at the N-terminal
primarily associated with E3 ubiquitin ligase activity and a
C-terminal responsible for tumor suppression and recruitment of
DNA repair enzymes [12]. When evaluating the two domains of
the BRCA1 protein, it was found that the C-terminal is not essential
for development. However, mice lacking the C-terminal were at
signiﬁcant risk of developing tumors as early as 1 month after
birth in a tissue- and time-dependent manner [13]. This ﬁnding
suggests that the multiple functions of BRCA1 in DNA repair are
not required for normal embryonic and fetal development at least
with respect to gross morphology. Evaluation of a number of other
DNA repair genes in mouse models has similarly shown that
progeny deﬁcient in DNA repair exhibit normal gross morphology,
but are more susceptible to developmental anomalies under con-
ditions of chemical and radiation stress [14–16].
BRCA1 plays an important role in multiple DNA repair path-
ways by either interacting directly with DNA repair proteins or
upregulating the expression of genes directly or indirectly in-
volved in DNA damage repair [17]. The importance of BRCA1 in
DNA repair has been demonstrated in non-homologous end join-
ing [17], homologous recombination repair [18], nucleotide exci-
sion repair [19] and base excision repair [20]. We have found that
deﬁciencies in several genes that are transcriptionally regulated by
BRCA1, including Cockayne Syndrome B (csb) [21] and oxoguanine
glycosylase 1 (ogg1) [14,16], do not affect morphological devel-
opment under controlled conditions, but result in increased sen-
sitivity to developmental anomalies caused by enhanced forma-
tion of reactive oxygen species (ROS) stimulated by teratogens like
methamphetamine (METH) and ethanol (EtOH).
Several lines of evidence implicate ROS in the mechanism of
EtOH teratogenesis. In embryo culture, ethanol induces the level of
ROS-producing NADPH oxidases (NOX), and this induction along
with ethanol-enhanced embryonic DNA oxidation and apoptosis
are blocked by a NOX inhibitor [22]. CYP2E1-mediated metabolism
of ethanol has also been shown to generate ROS as a byproduct
[23]. ROS levels are increased in embryos and fetuses exposed in
utero to ethanol, evidenced by DCF ﬂuorescence and oxidatively
damaged DNA [15,22,24–26]. Structural and cognitive changes
caused by ethanol in vivo are prevented with pretreatment by the
free radical scavenging agent α-phenyl-N-tert-butylnitrone (PBN)
[27]. Ethanol-initiated embryopathies and DNA oxidation in whole
embryo culture are respectively enhanced or reduced in geneti-
cally altered mice that either are deﬁcient in or overexpress the
antioxidative enzyme catalase, and ethanol embryopathies are
blocked by pretreatment with exogenous catalase [24,28].
ROS-dependent developmental anomalies correlate with a
marked increase in the formation of the oxidative DNA damage
lesion 8-oxo-2′-deoxyguanosine (8-oxodGuo). In the case of OGG1,
untreated homozygous ogg1-deﬁcient progeny exhibited increased
postnatal neurodevelopmental deﬁcits, demonstrating that even
physiological levels of ROS can be pathogenic in the absence of
adequate DNA repair [16]. The in utero death of homozygous brca1
knockout embryos may result from an overwhelming reduction in
several DNA repair genes that are crucial for development. How-
ever, the absence of gross morphological anomalies in hetero-
zygous progeny suggests that moderately reduced levels of BRCA1
have negligible developmental impact. A conditional knockout
mouse line targeting the dorsal telencephalon starting on E9.5
using Emx-1 directed Cre recombinase showed increased apop-
tosis in homozygous but not heterozygous brca1 knockout cells
[29].
Herein, we developed a conditional brca1 knockout model with
heterozygous (þ/) brca1 progeny that exhibit a modest 28%
decrease in BRCA1 protein levels and develop normally. However,
when exposed in culture to EtOH, þ/ BRCA1-deﬁcient embryosexhibited increased levels of oxidatively damaged DNA and em-
bryopathies compared to wild-type BRCA1-normal littermates,
showing that even modest deﬁciencies in BRCA1 increase em-
bryonic susceptibility to the pathological effects of drug-enhanced
ROS formation. These results reveal a broader biological role for
BRCA1 in protecting the developing embryo from oxidative stress,
and corroborate a role for DNA damage in the mechanism of
ethanol embryotoxicity.2. Materials and methods
2.1. Chemicals
EtOH was purchased from Commercial Alcohol Inc. (Brampton,
ON). Saline was purchased from Baxter (Mississauga, ON). Hanks’
Balanced Salt Solution, Waymouth’s MB 752/1 medium, fetal bo-
vine serum, proteinase K and calf intestinal alkaline phosphatase
were purchased from Life Technologies (Burlington, ON). Nuclease
P1 was purchased from Sigma Aldrich Canada (Oakville, ON).
2.2. Animals and diet
All animal studies were conducted in accordance with Cana-
dian Council on Animal Care standards and were approved by the
institutional Animal Care Committee. Mice containing LoxP sites
ﬂanking exon 11 of the brca1 gene (brca1LoxP/LoxP) were generously
donated by the Frederick National Laboratory for Cancer Research
(National Institute of Health, Frederick, MD). Hemizygous trans-
genic mice expressing Cre recombinase controlled by the Sox2
promoter (Creþ /) were obtained from Jackson Laboratories (Bar
Harbor, ME). All animals were housed in light- and temperature-
controlled rooms (14-h light/10-h dark cycle, 20 °C, 50% humidity).
Teklad 18% protein rodent chow (Harlan Laboratories, Mississauga,
ON) and tap water were provided ad libitum. The two colonies
were maintained separately and housed with up to four animals
per cage, separated by sex. For overnight matings, up to 3
brca1LoxP/LoxP females were housed with one male Creþ / from
17:00 to 9:00 and then separated. Females with a vaginal plug
(plug designated gestational day (GD) 1) were placed in separate
cages and were used as described below. Jackson laboratories has
noted that when the Sox2-Cre females are used for cross breeding
with ﬂoxed males, expression of Cre recombinase is ubiquitously
present in all embryonic tissues even if the transgene is not in-
herited. In contrast, when male Sox2-Cre mice are used, expres-
sion of Cre recombinase is limited to offspring that carry the
transgene, and is localized to cells of epiblast origin, starting on GD
6.5. Accordingly, only male Sox2-Cre mice were used in this study.
All offspring had one allele with LoxP sites located in the introns
ﬂanking exon 11 of the brca1 gene. Half of those offspring also
received the Cre recombinase transgene controlled by the Sox2
promoter, which results in the deletion of exon 11, the sequence of
DNA ﬂanked by the LoxP sites, starting on GD 6.5 [30]. Deletion of
exon 11 results in the truncation of the BRCA1 protein at the
C-terminal [31]. Mice lacking the Cre transgene developed nor-
mally in our laboratory.
2.3. Genotyping
After weaning, mice were ear tagged and a small notch was
removed from their ears for genotyping. For explanted embryos,
the visceral yolk sac was used for genotyping. Crude DNA extracts
were isolated using the HOTSHOT method [32]. Brieﬂy, ear notches
or visceral yolk sacs were placed in 75 mL of 25 mM NaOH con-
taining 0.2 mM EDTA for 1 h at 95 °C. Samples were then neu-
tralized with 40 mM Tris (pH 5.0) and stored at 4 °C. A 2 mL aliquot
Fig. 1. Representative gels to conﬁrm the breast cancer 1 (brca1) genotype of
mouse strains. (Panel A) Agarose gel of PCR products from crude DNA extraction
amplifying the Cre transgene (100 bp), with interleukin-2 as a positive control
(324 bp). The presence of both bands indicates that the Cre recombinase gene is
present, resulting in the heterozygous brca1-deﬁcient (def) genotype, while lanes
with only the upper band indicate an absence of Cre recombinase resulting in the
wild-type (WT) genotype. (Panel B) Representative gel for the brca1-loxP mice
showing the WT brca1 genotype. Each lane is from a different mouse, and mice
containing two copies of the ﬂoxed brca1 allele displayed a band at 500 bp. Only
mice homozygous for the ﬂoxed brca1 allele were used in this study.
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ampliﬁcation.
2.3.1. Cre transgenic mice
Genotyping of the Cre transgene was performed according to a
generic Cre protocol provided by Jackson Laboratories. The Cre
primers were as follows: F: 5′-GCGGTCTGGCAGTAAAAACTATC-3′,
R: 5′-GTGAAACAGCATTGCTGTCACTT-3′. Primers coding for inter-
leukin 2, used as a positive control, were: F: 5′-CTAGGCCACA-
GAATTGAAAGATCT-3′, R: 5′-GTAGGTGGAAATTCTAGCATCATCC-3′.
The PCR reaction conditions were as follows: 2.0 mM MgCl2,
0.2 mM dNTP, 1 mM of each primer and 0.01 U/mL Hot Start Taq
polymerase. After activation at 94 °C for 3 min, the reaction went
through 35 cycles of 94 °C for 30 s, 51.7 °C for 60 s and 72 °C for
60 s, followed by 72 °C for 2 min (Fig. 1A).
2.3.2. Floxed brca1 mice
To conﬁrm the presence of the LoxP sites, we used the fol-
lowing primers: F: 5′-CTGGGTAGTTTGTAAGCATGC-3′, R: 5′-CAA-
TAAACTGCTGGTCTCAGG-3′. The reaction mixture contained
2.5 mM MgCl2, 0.2 mM dNTP, 0.33 mM primers and 0.05 U/mL Hot
Start Taq polymerase. The PCR cycle included activation at 94 °C
for 3 min, 35 cycles of 94 °C for 1 min, 60 °C for 2 min and 72 °C for
1 min, followed by 72 °C for 3 min. The presence of a band at
500 bp indicated that the mice contained the LoxP sites (Fig. 1B).2.4. DNA isolation for oxidative DNA damage
Pregnant dams received a single intraperitoneal (i.p.) injection
of 4 g/kg EtOH or its saline vehicle (control) on GD 12 and were
sacriﬁced 6 h later by cervical dislocation. Embryos were quickly
removed from the uterus and all extraembryonic tissues were
removed. Small sections of the tail were collected for genotyping,
while the remaining embryonic tissues were snap frozen in liquid
nitrogen and stored at 80 °C for future analysis. DNA was iso-
lated from embryonic tissues using a modiﬁed version of the
chaotropic sodium iodide method described by Ravanat et al. [33].
Approximately 50–100 mg of wet tissue was homogenized in
a cold sucrose gradient lysis buffer (320 mM sucrose, 5 mM MgCl2,
10 mM Tris, 0.1 mM desferoxamine, 1% (v/v) Triton X-100,
pH¼7.5). Nuclear cell fractions were collected by centrifugation at
1,000 g for 10 min then resuspended in an enzyme reaction so-
lution containing 1% (w/v) SDS, 5 mM EDTA-NA2, 0.15 mM des-
feroxamine and 10 mM Tris–HCl, pH¼8.0. Digestion of con-
taminating RNA was accomplished by the addition of 624 and
312 U/mL of RNase A and T1, respectively, for 1 h at 50 °C. Protein
was digested by the addition of proteinase K to a ﬁnal con-
centration of 1.8 mg/mL for 1 h at 50 °C. DNA was precipitated out
by the addition of a saturating NaI solution (7.6 M NaI, 40 mM Tris,
20 mM EDTA-NA2, 0.3 mM desferoxamine, pH¼8.0) and protein
contaminants were removed by the addition of 100% isopropanol.
DNA was pelleted by centrifugation at 10,000 g for 10 min before
ﬁve rounds of washing in 70% (v/v) EtOH. The isolated pellet was
then dissolved in sodium acetate buffer (7.6 M NaI, 40 mM Tris,
20 mM EDTA-NA2, 0.3 mM desferoxamine, pH¼8.0) and analyzed
for absorbance at 260/280 nm for concentration and purity.
2.5. Digestion of DNA and analysis by enzyme linked immunosorbent
assay (ELISA)
A total of 100 mg of DNAwas placed in 200 mL of sodium acetate
buffer and incubated for 1 h at 37 °C with 5 U of nuclease P1 to
hydrolyze the DNA [33]. Nucleosidic phosphates were hydrolyzed
by calf intestinal alkaline phosphatase (6 U/20 mL per reaction) for
1 h at 37 °C following the addition of 1 M Tris–HCl buffer, pH 8.5,
to a ﬁnal pH of 8.0. Contaminating molecules of molecular weights
greater than 10 kDa were removed by ﬁltration using Amicon YM-
10 spin columns and centrifugation at 14,000 g for 1 h. The pur-
iﬁed samples were placed in a competitive binding High Sensitive
8-OHdG Check ELISA Kit and analyzed according to the manufac-
turer's speciﬁcations (Genox Corporation, Baltimore, MD, USA).
The bottoms of the ELISA plate wells were coated with a known
amount of puriﬁed 8-oxodGuo. When samples and an antibody
that speciﬁcally recognizes 8-oxodGuo were added, 8-oxodGuo
afﬁxed to the plate competed with free 8-oxodGuo from samples
for antibody binding. Visualization was carried out by the addition
of an HRP conjugated secondary antibody that oxidized tetra-
methylbenzidine, and the product, 3,3′,5,5′-tetramethylbenzidine
diimine, was measured by absorbance at 450 nm.
2.6. Western blotting
Pregnant dams received a single i.p. injection of 4 g/kg EtOH or
its saline vehicle (control) on GD 9 and were sacriﬁced 24 h later
by cervical dislocation. Embryos were quickly removed from the
uterus and all extraembryonic tissues were removed. Visceral yolk
sacs were collected for genotyping while whole embryos were
snap frozen in liquid nitrogen and homogenized in RIPA buffer
containing complete protease inhibitor cocktail tablets (Roche
Applied Science, Laval, QC). Protein content was determined by the
bicinchoninic acid (BCA) assay and 15 mg of total protein were
loaded in each well of a 10% (v/v) polyacrylamide gel under
Fig. 2. BRCA1 protein expression in conditional knockouts and wild-type embryos
by western blot analysis. Hemizygous Cre recombinase mice controlled by the Sox2
promoter were mated overnight (plug designated gestational day [GD] 1) with
female homozygous mice containing LoxP sites ﬂanking exon 11 of the brca1 gene,
resulting in either wild-type (WT) progeny with normal BRCA1 protein levels, or
BRCA1-deﬁcient (def) progeny with reduced protein levels. On GD 10, dams were
sacriﬁced by cervical dislocation and whole embryos were removed and snap
frozen. BRCA1 protein expression was quantiﬁed by western blot using GAPDH as a
loading control. *po0.05 compared to WT embryos.
A.M. Shapiro et al. / Redox Biology 7 (2016) 30–38 33reducing (50 mM DTT) conditions. After blocking for 1 h in blocking
buffer (Tris-Buffered Saline with Tween 20 [TBST]þ5% (w/v) milk),
BRCA1 blots were cut at the 70 kDa mark. The upper region of the
blot was probed against BRCA1 using a monoclonal antibody (R&D
Systems Cat#MAB22101), which recognizes the C-terminal of the
protein, at 1 mg/mL in blocking buffer. After washing, this upper blot
was probed with a goat anti-mouse-HRP (5000 dilution in
blocking buffer) (Santa Cruz Biochemical, Santa Cruz, CA) for 1 h. The
lower region of the blot was probed with mouse anti-GAPDH-HRP
(Sigma Aldrich Canada, Burlington, ON) at 50,000 dilution. Che-
miluminescent detection was achieved using ECL Plus western
blotting substrate (Thermo Scientiﬁc, Lafayette, CO).
For γH2AX, blots were probed with mouse anti-γH2AX, which
recognizes phosphorylation of Ser139 on H2AX (Abcam, cat#-
ab2893) at 2000 dilution overnight at 4 °C. Both primary anti-
bodies were probed with goat anti-mouse IgG conjugated to HRP
at 5000 dilution in 5% (w/v) milk for 1 h at room temperature.
Blots were washed with TBST and visualized using ECL-plus che-
miluminescent reagent (Thermo Scientiﬁc, Lafayette, CO). After
probing the blots for γH2AX, blots were washed in TBST and an-
tibodies were removed using Restore Plus Western Blot Stripping
Buffer (Thermo Scientiﬁc) for 10 min at room temperature. Fol-
lowing another blocking step in 5% (w/v) milk, blots were treated
with mouse anti-GAPDH-HRP (Sigma Aldrich Canada, Burlington,
ON) at 50000 dilution and visualized as described above.
2.7. Embryo culture
Pregnant dams were sacriﬁced on GD 9 by cervical dislocation and
the embryos were excised. All extra-embryonic tissues, with the ex-
ception of the visceral yolk sac and ectoplacental cone, were removed.
Growth medium (50 mL Waymouth's MB 752/1 medium, 500 μL of
50 U/mL penicillin and 50 mg/mL streptomycin in saline, 2.5 mM
HEPES, 15 mL fetal bovine serum and 35 mL male rat serum) was pre-
gassed with 5% CO2 in air for 30 min. Embryos with 7–8 somite pairs
were placed in individual wells on a 24 well plate in 2 mL of growth
medium containing EtOH or saline vehicle, enclosed with an airtight
seal on a platform rocker (Bellco Biotechnology, Vineland, NJ) for 24 h
at 37 °C in a Sanyo model MCO-17A CO2 incubator (Sanyo Electric Co.,
Ltd., Japan). Following incubation, embryos were assessed for the
following parameters: anterior neuropore closure, crown-rump
length, turning, head length, yolk sac diameter, number of somite
pairs and heart rate. Somite development and crown-rump length
were assessed only in those embryos that turned during the in-
cubation period. Embryos were scored only if they had a heart beat.
Visceral yolk sacs were removed for genotyping as described above.
2.8. Statistical analysis
Statistical analyses were performed using Prisms, Version 5
(GraphPad Software, Inc., San Diego, CA). Differences in BRCA1
expression were evaluated by Student's t-test. Other continuous
data, expressed as meanþSD, were analyzed by one-way ANOVA
with the Newman–Keuls post-hoc test for DNA oxidation and the
Bonferroni post-hoc test for γH2AX blots and embryo culture. Bi-
nomial data were analyzed using the Chi-square test. The minimal
level of signiﬁcance used throughout was po0.05.3. Results
3.1. Heterozygous brca1 conditional knockouts have less BRCA1
protein than wild-type littermates
Issues of embryolethality precluded the use of homozygous
brca1 knockouts for developmental studies. As a result, a Cre-Loxbased approach was used for gene removal during the embryonic
period, bypassing the critical period for embryolethality. To
achieve a full conditional knockout, however, mice heterozygous
for the brca1-ﬂoxed allele ﬁrst had to be characterized. Frequency
of genotypes appeared to follow Mendelian distribution, with an
approximately 1:1 ratio of wild-type (Cre absent) to conditional
brca1-deﬁcient (hemizygous for Cre) progeny. No phenotypic dif-
ferences were observed between the two genotypes. To determine
relative BRCA1 protein levels in the two genotypes, we employed a
western blot targeting the C-terminal of the BRCA1 protein. Fig. 2
shows the relative expression of BRCA1 protein in the wild-type
and þ/ brca1-deﬁcient mice by western blot. The þ/ brca1
conditional knockout mice, carrying one ﬂoxed allele and one
wild-type allele, had 28% less BRCA1 protein expression relative to
their wild-type littermates (po0.05) based on semi-quantitative
densitometry of western blots.
3.2. Brca1-deﬁcient embryos exhibit more oxidatively damaged DNA
than their wild-type littermates
BRCA1 is an important factor in DNA double strand break re-
pair, but also plays an important role in the transcriptional reg-
ulation of base excision repair (BER) [20]. Accordingly, we eval-
uated levels of 8-oxodGuo as a biomarker of DNA damage and BER
activity. More importantly, this DNA lesion has been shown in ogg1
knockout mice to contribute to the mechanism of neurodegen-
eration caused by 3,4-methylenedioxymethamphetamine (MDMA,
Ecstasy) in adults [34], and postnatal neurodevelopmental deﬁcits
caused by in utero exposure to methamphetamine [35] and EtOH
[16]. As shown in Fig. 3, EtOH caused an increase in 8-oxodGuo
levels compared to saline controls in both brca1wild-type (BRCA1-
normal) (po0.05) and þ/ brca1 knockout (BRCA1-deﬁcient)
(po0.001) embryos, indicating a consistent drug effect regardless
of brca1 genotype. Moreover, EtOH-treated BRCA1-deﬁcient em-
bryos had 13% higher levels of 8-oxodGuo compared to EtOH-
treated BRCA1-normal littermates (po0.05), indicating a gene-
Fig. 3. Brca1-deﬁcient (def) mice do not have increased levels of the oxidative DNA
damage lesion 8-oxo-2′-deoxyguanosine (8-oxodGuo), but are more susceptible to
ethanol (EtOH)-initiated DNA damage. Mice were bred as described in Fig. 2. On GD
12, dams received a single ip injection of 4 mg/kg EtOH or saline vehicle, and were
sacriﬁced 6 h later by cervical dislocation. Embryos were removed and snap frozen.
An aliquot of 100 mg DNA was isolated fromwhole embryos and analyzed by ELISA.
While no differences were observed in the saline-treated groups, EtOH-exposed
wild-type (WT) BRCA1-normal and heterozygous BRCA1-deﬁcient (def) embryos
had increased levels of 8-oxodGuo relative to their respective saline-treated con-
trols, representing a drug effect. EtOH-exposed deﬁcient embryos had elevated
levels of 8-oxodGuo compared to their WT littermates, indicating a brca1 gene
effect. *po0.05 compared to WT saline-exposed embryos, †po0.001 compared to
brca1-def saline-exposed embryos, ‡po0.05 compared to EtOH-exposed WT
embryos.
Fig. 4. Brca1-deﬁcient (def) embryos are more susceptible to ethanol (EtOH)-in-
itiated DNA double strand breaks. GD 10 embryos were explanted from dams
treated as described in Fig. 3, and homogenized in RIPA buffer in the presence of
protease inhibitors. DNA double strand breaks were measured by the presence of
γH2AX relative to GAPDH loading control by western blot analysis. γH2AX levels
were unaffected by brca1 genotype in saline-treated control embryos. However,
maternal treatment with EtOH increased phosphorylation to form γH2AX in brca1-
deﬁcient (def) embryos compared to both brca1-deﬁcient saline-exposed progeny
(po0.001), and their EtOH-exposed wild-type (WT) littermates (po0.05). † in-
dicates a difference from saline-exposed WT littermates that was signiﬁcant by
Student t-test (p¼0.017), but not by ANOVA (p¼0.082).
A.M. Shapiro et al. / Redox Biology 7 (2016) 30–3834dependent increase in oxidatively damaged DNA. The brca1 gen-
otype had no signiﬁcant effect on 8-oxodGuo levels in saline
controls, although a small and non-signiﬁcant trend for an in-
crease in BRCA1-deﬁcient embryos was observed.
3.3. EtOH-treated brca1-deﬁcient embryos have increased expres-
sion of γH2AX relative to their wild-type littermates and vehicle
controls
Following the formation of a DNA double strand break (DSB),
H2AX is phosphorylated at Ser139, forming γH2AX, to recruit other
DNA repair factors to the damaged site. This makes γH2AX a ro-
bust biomarker for DNA DSBs, as well as a molecular complement
to the oxidative DNA lesion 8-oxodGuo. As shown in Fig. 4, EtOH
treatment increased γH2AX formation compared to saline controls
by 4.2-fold in BRCA1-deﬁcient embryos (po0.001), indicating a
drug effect. A similar 2.3-fold increase in γH2AX in EtOH-treated
wild-type BRCA1-normal littermates was signiﬁcant by Student's
t-test (p¼0.017), although not by ANOVA (p¼0.082). As observed
for the 8-oxodGuo lesion, EtOH-treated BRCA1-deﬁcient embryos
exhibited a γH2AX level that was 75% higher than that in EtOH-
treated wild-type BRCA1-normal littermates (po0.05), conﬁrming
a gene-dependent increase in DNA damage. No difference was
observed between the BRCA1-deﬁcient mice and their wild-type
littermates when treated with saline vehicle.
3.4. BRCA1-dependent effect on EtOH embryopathies in mouse
whole embryo culture
To determine the effect of a BRCA1-deﬁciency on development,
embryos were cultured and assessed for a number of structural
and functional parameters (Fig. 5). In saline-treated groups, nogenotypic differences in any parameter were observed between
wild-type and BRCA1-deﬁcient embryos, and deﬁcient embryos
appeared to be normal. An EtOH concentration of 4 mg/mL was
chosen as a threshold concentration based on previous work in
ogg1 knockout strains with a similar genetic background [15]. At
this concentration, no difference in any parameter was observed in
wild-type animals exposed to EtOH compared to saline controls.
Upon challenge with 4 mg/mL EtOH, wild-type embryos exhibited
no abnormality in any morphological parameters compared to
saline controls, although a 22% increase in heart rate was observed
(po0.001). In contrast, EtOH-exposed BRCA1-deﬁcient embryos
exhibited signiﬁcant pathological changes in a number of para-
meters compared to both saline-treated littermates, indicating a
drug effect, and compared to EtOH-treated wild-type BRCA1-nor-
mal littermates, indicating a gene effect. Brca1 gene effects were
evident for EtOH-initiated abnormalities in anterior neuropore
closure, turning, head length and somite development in BRCA1-
deﬁcient embryos compared to wild-type littermates (po0.05).4. Discussion
Our results show that mouse embryos with even a modest 28%
reduction in BRCA1 protein levels develop normally but are at
greater risk of abnormal development under conditions of rela-
tively low oxidative stress that do not affect BRCA1-normal lit-
termates. This suggests a broader biological role for BRCA1, not
only beyond cancer, but also for embryos with only modest BRCA1
deﬁciencies. Such deﬁciencies could result from inherited þ/
gene mutations or a multitude of other mechanisms, including
epigenetic modiﬁcations that only modestly reduce BRCA1 levels
and/or binding activity. Accordingly, the risk for BRCA1-dependent
developmental abnormalities, including those due to a þ/ brca1
genotype, would be expected to be substantially greater than that
for breast and ovarian cancers, most of which require mutation of
both brca1 alleles resulting in a / brca1 genotype [36]. A cor-
ollary arising from the protective role of BRCA1 observed herein is
Fig. 5. Brca1-deﬁcient embryos are more susceptible to ethanol (EtOH) embryopathies. Male mice hemizygous for Cre recombinase controlled by the Sox2 promoter were
time mated for 2 h (plug designated GD 0) with female mice that homozygously contained LoxP sites ﬂanking exon 11 of the brca1 gene, resulting in wild-type (WT) and
heterozygous (def) brca1 littermates respectively exhibiting normal and deﬁcient levels of BRCA1 protein. On GD 9, BRCA1 WT and deﬁcient 6-8-somite embryos were
explanted and incubated for 24 h with EtOH (4 mg/ml) or its saline vehicle. Embryos were evaluated under a microscope for morphological and functional (heart rate)
factors. Daggers for EtOH-exposed groups indicate a difference from saline controls with the same brca1 genotype (drug effect) (††po0.05, †††po0.001), and asterisks for
EtOH-exposed BRCA1-deﬁcient groups indicate a difference from wild-type littermates exposed to the same EtOH treatment (brca1 genotype effect) (po0.05).
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the mechanism of EtOH embryopathies, which may ultimately
prove relevant to the mechanism and risk factors for a broader
range of developmental abnormalities in Fetal Alcohol Spectrum
Disorders (FASD).
We anticipated the developmental impact of modest BRCA1
deﬁciencies under conditions of oxidative stress, as it has been
shown that deﬁciencies in several genes that regulate or aredirectly involved in base excision repair can still result in normal
developmental phenotypes [35,37,38], but are more susceptible to
ROS-initiating teratogens [14–16,21]. The association of increased
levels of DNA damage with both structural and functional deﬁcits
suggests that xenobiotic-initiated oxidative stress is causing oxi-
datively damaged DNA, particularly the 8-oxodGuo lesion, which if
not repaired, can initiate changes in gene expression resulting in a
number of developmental pathologies. A pathogenic role for
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and postnatal neurodevelopmental deﬁcits [16] in ogg1 knockout
progeny exposed respectively in culture or in utero to EtOH.
Brca1-deﬁcient mice had a 28% reduction in BRCA1 protein
expression when carrying one allele that codes for the functional
protein and one that is missing exon 11, resulting in a decrease in
BRCA1 protein levels. Assuming complete excision of ﬂoxed brca1
by Cre recombinase, we expected a somewhat greater suppression
of protein levels. In lymphoblastoid cell lines derived from cancer
patients whose tumor cells exhibit / brca1 mutations, BRCA1
protein expression was between 69% and 81% lower than wild-
type levels [39]. A possible explanation for the discrepancy be-
tween our protein levels and those found in vitromay be related to
the high turnover rate of BRCA1, which is controlled in part by
proteolytic degradation [40,41]. In vitro, BRCA1 protein was found
to have a half-life of 2 h, while in the presence of proteolytic in-
hibitors, the half-life increased to 6 h [42]. It is possible that a
regulatory mechanism may attempt to compensate for the re-
duction by decreasing proteolysis. The relatively high turnover
rate may suggest the need for tight regulation of the protein,
possibly because of poor stability or overactivity. Overexpression
of brca1 in cell lines with normal levels of retinoblastoma protein
has been shown to reduce cell colony formation [43]. It remains to
be seen whether the protein levels observed in our study re-
present a population of proteins that evaded proteolysis, resulting
in a population of aged BRCA1, or if the observed protein is of the
same quality as that found in the wild-type controls resulting from
incomplete Cre-mediated DNA digestion. The fact that this mini-
mal level of suppression resulted in morphological and biochem-
ical changes suggests that a very small depletion of BRCA1 is
sufﬁcient to increase susceptibility to teratogens.
Numerous forms of oxidatively damaged DNA result from the
interaction of DNA with ROS, with the formation of 8-oxodGuo
being the most prevalent due to the low reduction potential of
deoxyguanosine (dGuo) [44]. EtOH has been shown to enhance
the ROS-mediated formation of 8-oxodGuo [15,22,25,28,45], and
elevations in 8-oxodGuo levels can lead to morphological
anomalies in the developing embryo [15] and postnatal neurode-
velopmental deﬁcits [16]. In this study, we similarly observed an
increase in DNA damage in both a drug- and brca1 gene-depen-
dent fashion. More directly, our manuscript demonstrates for the
ﬁrst time an increase in levels of the oxidative DNA lesion 8-oxo-
dGuo in BRCA1-deﬁcient progeny that are exposed to ethanol.
Although we cannot at the current time measure oxoguanine
glycosylase 1 (OGG1) activity in these mice, 8-oxo-dGuo lesion in
mammals is primarily repaired by OGG1 [46], so a BRCA1-de-
pendent decrease in OGG1 activity is a likely mechanism for the
enhanced levels of 8-oxo-dGuo. This mechanism is supported by
the reported role of BRCA1 in directly enhancing both OGG1
transcription and activity [47], as well as the activation of nuclear
factor erythroid 2-related factor 2 (Nrf2) [48], the latter of which
we have recently shown enhances ogg1 gene expression [49]. A
decrease in OGG1 activity underlying the enhanced susceptibility
of BRCA1-deﬁcient progeny exposed to ethanol is also consistent
with the enhanced susceptibility of ogg1 knockout progeny to
ethanol-initiated embryopathies in culture and fetal DNA oxida-
tion and postnatal neurodevelopmental deﬁcits following in utero
ethanol exposure [15,45].
In addition to the effects on DNA repair, BRCA1 has been shown
to play important roles in other pathways through transcriptional
regulation. A microarray study found that cells transfected with
brca1 had increased expression of several genes involved in de-
toxiﬁcation of reactive intermediates, such as aldehyde dehy-
drogenase and antioxidative enzymes [50]. Antioxidative defenses,
regulated by Nrf2, are upregulated by BRCA1 [48,51]. This combi-
nation of compromised detoxiﬁcation of reactive intermediatestogether with reduced DNA repair may collectively predispose
brca1-deﬁcient progeny to the pathogenic effects of ROS.
The use of mouse whole embryo culture provides a valuable
tool for addressing embryonic susceptibility to chemical exposure
in the absence of confounding maternal inﬂuences. In this study,
we found that brca1-deﬁcient embryos exposed to EtOH showed
signiﬁcant reductions in anterior neuropore closure, head length,
turning and somite development. While these parameters do not
necessarily predict structural impairments, they provide a snap-
shot of the state of embryos at a critical point in development. A
number of parameters were affected in brca1-deﬁcient embryos
that represent different cellular targets: anterior neuropore clo-
sure and head length are both representative of toxicity to neural
crest cells (NCCs), consistent with cell culture studies in which co-
treatment of NCCs with EtOH and free radical scavengers resulted
in increased cell viability and decreased free radical production
compared to EtOH exposure alone, revealing a free radical-de-
pendent mechanism of toxicity [52]. Somite development, which
originates in paraxial mesoderm [53], is affected by EtOH treat-
ment around gastrulation by preventing the formation of la-
mellipodia in cells of mesodermal origin [54]. While the latter has
not been investigated for its association with ROS, the deﬁciencies
in somite development observed may be the result of disruptions
to NCC signaling, direct interaction of ROS with mesodermal tis-
sues or involvement of a signaling cascade common to NCC and
mesoderm, such as the Wnt signaling pathway. Wnt6 is essential
for proper development of somites [55] and neural crest cells [56].
Embryo culture studies in which C57BL/6 mice were exposed to
EtOH revealed epigenetic changes to various genes including Wnt6
that correlated with changes in expression at the RNA level [57].
This epigenetic modiﬁcation may be related to the reduction of
DNA repair associated with BRCA1 deﬁciencies.
It is interesting to note that while embryopathies in culture are
commonly reported with the concentration of EtOH used herein
[15,58], BRCA1 wild-type embryos were not affected. We have
previously found that inbred C57BL/6 mice are susceptible to
embryopathies at this concentration while outbred CD-1 mice are
similarly susceptible only at a higher concentration [27]. The re-
lative strain resistance of the wild-type brca1 mice to EtOH em-
bryopathies may be the result of cross breeding between the Cre
transgenic mice with the ﬂoxed brca1 strains.
While breast cancers associated with mutated brca1 are char-
acterized by a loss of both functional alleles [59], the embry-
olethality associated with carrying two non-functional alleles [8]
means that mutation of only one brca1 allele can be present
throughout early embryonic development, since one wild-type
functional allele is essential for survival during that period. Mu-
tation of the second brca1 allele could be acquired during late
embryonic or fetal development, or postnatally. Our heterozygous
brca1 knockout mice accordingly represent a clinically relevant
model for studying the developmental consequences of BRCA1
deﬁciencies. We used conditional knockout mice that express
normal levels of BRCA1 until GD 6.5 when Cre recombinase ex-
pression leads to the deletion of exon 11 on one brca1 allele [31],
which is the same region deleted in the embryolethal brca1
knockouts [3]. This approach offers the beneﬁt of testing appar-
ently healthy progeny in which the loss of brca1 roughly coincides
with the embryo culture period. Unlike our conditional knockout
approach, conventional knockouts may have indirect pathologies
associated with the absence of brca1 from conception, which could
confound interpretation. The signiﬁcant developmental impact
observed with the modest 28% decrease in embryonic BRCA1
protein in our conditional heterozygous brca1 knockout model
suggests that BRCA1 plays a major role in protecting the embryo
and fetus from environmentally enhanced developmental oxida-
tive stress, which would not be discerned from adult human
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be useful to have more human information on the range of BRCA1
levels and binding activity to its various partners, with deﬁciencies
potentially arising from a spectrum of mechanisms including gene
mutations, altered regulation by miRNAs and post-translational
changes affecting protein levels and binding activity, one or more
of which may differ in the embryo and/or fetus compared to
analyses in adults in cancer studies.
In the adult human population, no differences in markers of
oxidative stress have been observed in individuals with brca1
mutations [60], which is consistent with our ﬁndings in the saline-
treated brca1-deﬁcient embryos. Similarly, no differences in mis-
carriage rates have been observed between brca1 mutation car-
riers and the general population [6,7]. However, it is possible that
brca1-deﬁcient individuals who are not exposed to ROS-enhancing
environmental conditions may be masking an enhanced devel-
opmental risk in that subset of the population. As importantly,
measurements of oxidative stress in adults will not reﬂect their
own history of ROS levels in utero, nor will the mother's level of
oxidative stress during pregnancy necessarily reﬂect the prox-
imate levels of ROS in their embryo or fetus [61].5. Conclusions
Our discovery that brca1-deﬁcient mice develop normally un-
der controlled conditions but are more susceptible to the em-
bryopathic effects of EtOH provides the ﬁrst direct evidence that
moderately decreased levels of BRCA1 constitutes an important
risk factor for teratogenesis initiated at least by this drug, and
possibly by other ROS-enhancing environmental conditions. More
information is needed concerning the human incidence and se-
verity of BRCA1 deﬁciencies due not only to brca1 mutations, but
also other mechanisms leading to diminished BRCA1 protein levels
and binding activities, particularly in the embryo and fetus. Our
results may have implications for recommended diet and pre-
scription drug use for pregnant women carrying offspring with a
single brca1 mutation.Conﬂict of interest
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